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EARLY DEATH OR RETRANSPLANTATION IN ADULTS AFTER 
ORTHOTOPIC LIVER TRANSPLANTATION 
CAN OUTCOME BE PREDICTED? 1 
HOWARD R. alvibI~ IGNAZIO R. ~1AofklI NICHOLAS JABBOUR, GIORGIO ZETII, JOHN MCMICHAEL, 
SANDI MITCHELL, JOHN FUNG, Al'-.'D THOMAS E. STARZL 
Pittsburgh Transplantation institute. University of Pittsburgh School of Medicine. Pittsburgh. Pennsylvania 
Early, reliable outcome prediction after a liver 
transplant would help improve organ use by minimiz· 
ing unnecessary retransplantations. At the same time, 
early intervention in those cases destined to fail may 
ameliorate the high morbidity and mortality associ· 
ated with retransplantation. The purpose of this study 
was to analyze several parameters that have been 
identified in the past as being associated with patient 
and graft outcome, and to try to develop a model that 
would allow us to make predictions based on data 
available in the early postoperative period. 
A total of 148 patients were followed in a prospec-
tive. observational study. Graft failure was defined as 
patient death or retransplantation within 3 months of 
surgery. Preoperative variables studied included pa-
tient demographics, need for life support. presence of 
ascites, serum bilirubin, serum albumin, prothrombin 
time. serum creatinine, and the results of the cytotoxic 
crossmatch. During the first 5 postoperative days, 
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standard measurements included serum transami-
nases, serum bilirubin, ketone body ratio, prothrom-
bin time, factor V, and serum lactate. Oxygen con-
sumption was measured shortly after surgery, once 
the patients had rewarmed to 36°C. 
There were 131 successful transplants (88.6%) and 17 
failures (IUi%). Most of the variables studied were 
found to be associated with outcome (by univariate 
analysis) at different points in the early postoperative 
period. However, receiver operating characteristic 
curve analysis showed that the predictive ability of 
even the best parameter was not adequate to make 
decisions on individual patients. Multivariate analy-
sis. using stepwise logistic regression, yielded a model 
with an overall accuracy of 92.7%. Again, receiver op-
erating characteristic curve analysis Bugge"ted that 
this model did not achieve the discriminating power 
needed for routine clinical use. 
We are still not able to accurately predict outcome in 
the early posttransplant period. We must be very care-
ful when evaluating parameters. or scoring systems, 
that are said to accomplish this. It is especially impor-
tant in this era of COlt containment, with ita renewed 
pressures to guide therapy based on our perceived un-
derstanding of a patient's future clinical course. 
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Predicting the outcome soon after liver transplantation re-
mains an elusive goal, although the need to anticipate the 
result of a therapeutic intervention is particularly compelling 
in lifesaving organ transplantation. We would like to deter-
mine early whether an organ is destined to fail, since early 
intervention might ameliorate the increased morbidity and 
mortality that accompany retransplantation. The reverse is 
also true. Given the donor shortage, we need to be able to 
determine confidently when it is indicated to manage the 
patient expectantly, so we will not waste a scarce societal 
resource. 
Several methods have been brought forth, all aimed at 
helping clinicians make an early determination regarding 
the ultimate fate of both the graft and patient. Many consist 
of simply examining individual parameters, such as clotting 
factors (1, 2), arterial ketone body ratio EP~FI lidocaine me-
tabolism (7), oxygen consumption (8-10), and serum lactate 
(11). Others are reasonably complex scoring systems that, 
presumably, model biological reality more closely (12-16). 
At present, no method has been adopted for general clinical 
use, if by this we mean making difficult individual decisions 
based upon them. Some are limited by incorporating subjec-
tive information that is difficult to standardize and quantify, 
such as our overall clinical impression regarding the degree 
of malnutrition in cirrhotic patients (12). Others cannot be 
used in certain subpopulations. such as insulin-dependent 
diabetics, patients with pancreatitis, or those who are starv-
ing (3,4). 
The purpose of our study was to analyze several factors 
that empirically have been shown to be associated with pa-
tient and graft outcome after liver transplantation. We 
wanted to determine whether recent advances in this field 
have changed the significance of some of these factors, and 
whether we can develop a model that will allow early predic-
tion of patient and graft outcome. based on data available in 
the early postoperative period. 
MATERIALS AND METHODS 
Patient Population 
From January to August 1992. 149 adult patients undergoing liver 
transplantation at Presbyterian University Hospital. Pittsburgh, PA. 
were entered into the study. They were followed prospectively for at 
least 3 months. Six patients that either died on the operating table or 
did not survive more than 24 hr were excluded. The study patients 
underwent a total of 156 transplants. but to keep the observations 
independent. only the initial transplant IS included in our analysis. 
We also excluded a young woman who died of intractable supraven-
tricular arrhythmias 23 days after the operation. This patient was 
transplanted for Budd-Chiari syndrome. and required a direct anas-
tomosis between the suprahepatic vena cava and the right atrium. 
She developed arrhythmias immediately after transplant that were 
attributed to direct trauma to the conduction svstem. At the time of 
her death from a cardiac arrest. she had norm~1 graft function. This 
left 148 patients. who formed the basis for this report. 
Parameters Studied 
Preoperative mformatlon included age and sex. number of liver 
transplants lincluding the index transplant). whether the patient 
was m the mtenslve care unit (lCU)·, need for mecharucal ventila-
• AbbreVIations: AKBR. arterial ketone body ratio; AUC. area un-
der the receiver operating charactenstic curve; ICU. intenSIve care 
urut; POD. postoperative day; ROC. receiver operating charactens-
tic; SGPT. serum glutamlc pyruVIC tranaanunase; SGOT. serum glu· 
tamlC oxaloacetlc transaminase. 
tion immediately before tranaplantation, presence of ascites. total 
serum bilirubin. serum albumin. prothrombin time, serum creati-
nine, and results of the cytotoxic CfOssmatch. 
After surgery, patients were allowed to rewarm to 36°C, at which 
time the central venous pressure (CVP) and pulmonary wedge pres-
sure were measured by means of a pulmonary artery catheter. The 
cardiac output (CO) was determined using the thermodilution 
method, with a cardiac output computer (COM-I, Irvine, CAl. The 
mean arterial pressure (MAP) was measured via an indwelling ra-
dial or femoral arterial catheter. Arterial and mixed venous blood 
samples were obtained for determinations of hemoglobin concentra-
tion and gas teIl8ions using a blood gas analyzer (ABL-4, Radiometer, 
Copenhagen, Denmark). The following values were then calculated 
using standard formulas: 
cardiac index (Cn = COlbody surface area 
systemic vascular resistance index (SVRIl = MAP - CVP • SOleI 
arterial oxygen content (Ca02) = lib • 1.39 • Sa02 + 0.003 • Pa02 
venous oxygen content (CvOz) = lib • 1.39 • Sv02 + 0.003 • Pv02 
arteriovenous oxygen difference (AVDOz) = Ca02 - Cv02 
oxygen delivery (002) = CI • Ca02 • 10 
oxygen COIl8umption (VOzl = CI • AVDOz 
During the first 5 days after surgery, we recorded the total serum 
bilirubin, serum aspartate aminotranaferase, serum alanine amin-
otransferase, serum lactate. arterial ketone body ratio (AKBRl. fac-
tor V. and prothrombin time. These measurements were all part of 
our routine postoperative protocol. AKBR was determined as de-
scribed previously (4). If the team managing the patient ordered 
several measurements in a given day, we recorded only those values 
that were obtained close to, and were available for. morning rounds. 
The only intraoperative parameter analyzed was the peak serum 
lactate. Other variables associated with the surgery, or the donated 
organ, have been identified as having prognostic significance. We 
postulated that their influence would translate into a recognizable 
postoperative state, and did not include them. The decision to re-
tranaplant was made by the clinical team caring for the patient. in 
consultation with the most experienced members of the tranaplant 
division. Since the study was strictly observational. and patients 
were treated according to our established clinical protocols, iIl8titu-
tional review board approval was not necessary. 
Definitions. Graft failure: patient death or retransplantation 
within 3 months of surgery m patients who survlVed at least 24 hr 
after the operation. Patient groups: group I, patients who underwent 
a successful transplant. that is. who survived more than 90 days 
without need for retranaplantion; group II. patients who had graft 
failure, as defined above. Primary nonfunction: lacking a technical 
complication. a graft that never demonstrates evidence of initial 
function, such that retransplantation has to be carried out within 2 
weeks of the onginal operation. or the patient succumbs to liver 
failure before a suitable graft can be obtained. Sepsis: systemic re-
sponse to infection, manifested by 2 or more of the following--{ 1) 
temperature> 38°C or < 36°C, (2) heart rate> 90 beats/min, (3) 
respiratory rate> 20 breathslmin or PaCOz < 32 torr. (4) white blood 
cells> 12.000 celllmmJ • < 4.000 ceUslmmJ. or > 10% immature lband) 
forms U7l. Seuere sepsis: sepsis associated with organ dysfunction. 
hypoperfusion. or hypotenSion l17). 
StatIstical Analvsis 
Continuous data are presented as the mean :!: SEM. Categoncal 
data are presented as frequencies. For continuous data. independent 
two-tailed t tests were used to determme whether there was a dif-
ference between groups. With the level of significance set at 0.05. The 
Levene test was used to determme whether the population variances 
were unequal. in which case a separate-vanance t test was used 
instead. In cases in which the distribution of the data was highly 
skewed. a log tralUltormation was also pertormed. and both trans-
formed and untransfonned data were tested for significance. Pear-
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son's chi-square statistic was used to test for differences in data 
expressed as frequencies. with the level of significance set at 0.05. 
Stepwise logistic regression analysis was used to derive an expres-
sion to calculate the probability of graft failure in a given patient. 
Several models were constructed, using both forward stepwise selec-
tion and backward elimination, with a likelihood ratio test to deter-
mine which variables should be removed from the model. The final 
model was adopted based on general accuracy, interpretability. and 
receIver operating characteristic (ROC) curve analysis. 
To evaluate the predictive power of individual tests, and that of the 
logistic regression models, ROC curve analysis was performed using 
software ( Labroc 1) kindly provided by Dr. Charles Metz, Department 
of Radiology. University of Chicago, Chicago, IL. All other calcula-
tions were done USIng SPSS for Windows. 
RESULTS 
Of 148 patients analyzed, 131 (88.5%) were successful ac-
cording to our definition <group nand 17 (11.5%) failed 
(group m. 
Cause of Graft Failure 
Severe sepsis: Seven graft failures were due to patient 
death from severe sepsis, occurring 2-64 days after trans-
plantation. Pancreatitis: One patient died of acute necrotiz-
ing pancreatitis 30 days after being retransplanted for recur-
rent hepatitis B. Arrhythmias: One patient died after 
developing ventricular tachycardia and subsequent fibrilla-
tion 3 days after surgery. He had no predisposing cardiac risk 
factors. Primary nonfunction: There were 3 instances of pri-
mary nonfunction. Ischemic injury: Four grafts were lost due 
to severe ischemic injury 16-90 days after transplantation. 
Rejection: Only 1 graft was lost to uncontrolled acute rejec-
tion. with severe central venulitis, 33 days after transplan-
tation. 
Preoperative Clinical Variables 
Table 1 shows the preoperative clinical characteristics of 
both groups. The only preoperative factors that were statis-
tically associated with outcome were serum creatinine and 
whether the patient was undergoing a retransplantation. 
The difference in total serum bilirubin was only of marginal 
significance (P=0.05), and this was also the case in the sub-
group of patients whose preoperative serum bilirubin was 
greater than 3 mgldl (46.4% of group I and 70.6% of group II. 
P=0.061. There were no differences in terms of age and sex. 
presence of asci tes. degree of hypoalbuminemia. prolongation 
of prothrombin time, or whether the patient was leU bound 
TABLE 1. Demographics and selected preoperative parameters 
for patients WIth successful (group Il and failed (group III 
grafts 
Group I Group II 
<n=1311 In= 17) 
Age Iyrl 49.5::: 1.2 53.1:::2.9 NS 
Sex l~ffcF 76/55 12/5 NS 
ICU bound 32% 53% NS 
Mechamcal ventilation 15.6% 23.5% NS 
Retransplantatlon 11.2% 35.3% P<O.Ol 
Total bilirubin (mgldll 82:::0.97 17.5:::4.3 P=0.05 
Prothrombin time Isec) 14.6=0.23 14.5:::0.53 ~p 
AlbumIn Igldl) 3.22:::0.07 2.9:::0.17 NS 
CreatInIne (mgJdl) 1.42:::0.11 2.1=0.32 P<0.05 
AsCItes 69.8% 75% NS 
Positive crossmatch 14.3% 0% NS 
or required mechanical ventilation before the transplant. 
There were no patients in group II who had a positive cyto-
toxic crossmatch, whereas 14.3% of those in group I had a 
positive crossmatch (7.6% strong positive, 5% positive, and 
1.7% weakly or doubtful positive). This difference, however. 
was not significant (P=0.1). 
Postoperative Clinical Variables 
Figure 1 shows the postoperative behavior of serum biliru-
bin, creatinine. lactate, and AKBR. The differences in the 
serum bilirubin became more pronounced during the early 
postoperative period, Mean serum bilirubin on postoperative 
day (POD) 1 was 7.6=0.47 mg/dl in group I and 12.1=1.7 
mg/dl in group II (P=0.02). By POD 5, the mean value in 
group I had decreased to 5.9=0.47, but in group II it had 
increased to 15.4=2.4 (P<O.Ol). This was not due to preop-
erative differences that were carried into the postoperative 
period. If we set to 1 the value of serum bilirubin on POD 1, 
in group I it declined to 0.83=0.04 by POD 2, while in group 
II it increased to 1.24=0.13 (P<O.Ol). By POD 5, the bilirubin 
ratio in group I was 0.91=0.06, whereas in group II it had 
increased to 1.74=0.32 (P=0.02). So, on average, serum bil-
irubin decreases slightly in the early postoperative period in 
successful grafts, while it increases significantly in failed 
grafts. 
Serum creatinine increased in both groups after the opera-
tion, but did so at a much higher rate in group II. Whereas 
the serum creatinine on POD 1 was 1.26=0.07 in group I and 
1.64=0.23 in group II (NS). it had gone up by POD 5 to 
1.59=0.09 in group I and 3.1=0.46 in group II (P<O.Ol). 
The AKBR tended to be higher in group I, but the differ-
ence between the 2 groups was significant only on POD 1 
(1.02=0.04 vs. 0.8::0.08, P<O.05)' Peak lactate during sur-
gery was 9.9::0.37 mmol/L in group I and 10.5:: 1.2 in group 
II (NS). Postoperative serum lactate was higher in group II. 
although it tended to normalize during the early postopera-
tive period in both groups. Differences were significant on 
POD 2 (2.2::0.1 for group I vs. 3.3::0.53 for group II. P<0.05) 
and POD 5 (1.8::0.1 for group I vs. 2.9::0.4 for group II, 
P<O.Ol). 
Figure 2 shows the behavior of serum transaminases, fac-
tor V. and prothrombin time in the early postoperative pe-
riod. The serum glutamic oxaloacetic transaminase (SGOT) 
decreased steadily in both groups, from 1458=153 (group l) 
and 2424::753 (group II) on POD 1 down to 135=14 (group Il 
and 241::61 (group II) by POD 5. These differences were 
significant only on POD 3. The serum glutamic pyruvic 
transaminase (SGPT) values on POD 1 were 924=84 (group 
1) and 1256::323 (group II) and rose transiently on POD 2 
before starting to decline. However, due to the small size of 
group II and the large variance, this observation is probably 
of little significance. By POD 5, SGPT had decreased to 
394::':33 (group Il and 572::': 133 (group m. None of these 
differences reached statistical significance. Factor V rose 
steadily and linearly throughout the early postoperatIve pe-
riod. It was significantly higher in group I on POD 2 (0.56:: 
0.03 vs. 0.39::0.08. P<0.05), POD 3 (0.8::0.04 VB. 0.47::':0.1. 
P<O.O ll, and POD 5 (1.09::':0.04 vs 0.75 ::0.1. P<O.Oll. Pro-
thrombin time on PODs 2-4 also correlated well with out-
come, although the trend was the same in both groups. Group 
I patients had a mean prothrombin time of 14.7::0.27 sec on 
POD 2, while in group II patients, it was 19.6::':1.56 sec 
1 
\ 
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(P<O.Oll. By POD 4, the prothrombin time had decreased to 
12.7:!:O.12 in group I and 1RKP~1K1 in group II (P<O.05). 
To compensate for the unequal variances. and the fact that 
most of these data had a highly skewed distribution. a log 
transformation of selected variables was done. This revealed 
that the differences between groups were significant during 
much of the observation period for both SGOT (P<O.Ol on 
days 2 and 3. and P<O.05 on days 4 and 5) and SGPT (P<O.05 
on days 2-41. Similar results were obtained when transform-
ingAKBR (P<O.05 on days 1. 3. and 5). serum lactate (P<0.05 
on davs 2 and 3, and P<O.Ol on day 5). and preoperative 
serum bilirubin (P=O.03). 
Table 2 shows the area under the ROe curve (AUe) for 
variables measured on POD 2 and POD 3. as well as multi-
variate models generated for those days using logistic regres-
sion analysis lsee beiowl. An ROe curve is obtained by plot-
ting the true-positive fraction against the false-positive 
fractIOn. It describes the ability of a test to discriminate be-
tween disease and nondisease. and is independent of preva-
lence lIB L In our particular case. we are measuring their 
ability to correctly classify patients as either belonging to the 
"uccessful or failed graft groups. An AUe of 1 means the test 
has perfect discrimmation. whereas anAUe of 0.5 means it is 
no better than chance. We can see that. individually. serum 
bilirubin performs better than any of the other biochemical or 
hematological parameters measured on those days. Serum 
creatimne and prothrombin time follow. There also is a ten-
dencv toward improvement in the discriminatory ability of 
some parameters. as we go from POD 2 to POD 3. Tables :3 
and 4. however. give us a better idea as to how these tests 
translate 111 actual practice. If we take the individual param-
eter wah the best overall performance. serum bilirubin on 
POD 3. we can see what happens as we vary the cutotTvalue 
':: significant 
that we use to decide whether the test is "abnormal" or not. 
that is. the point at which we would consider the test indica-
tive of eventual graft failure. If we set this point at 23.5 
mg/dl, we obtain a high degree of specificity <the false-posi-
tive fraction is only 2%). but at the cost of a very low sensi-
tivity (true-positive fraction of only 16%). As we lower the 
cutoff value. the sensitivity increases. but so does the false-
positive fraction. To obtain a sensitivity of 75%. we need to be 
willing to accept a false-positive fraction of 15%. 
Oxygen delivery Eal:!m~ I in the early postoperative period 
was 727 ~ 18 mllm~ in group I. while in group II. it was 
SOR~49 mllm~ (NS). Oxygen consumption Esl/m~F was 
1O4~O mllm2 in group I and 1RM~OP mllm2 in group II (NS). 
There was no difference in the core temperature between the 
2 groups at the time these measurements were made EPSK4~ 
O.l°e vs. PSKO~lKf°eFK 
Several models were generated. using logistic regression 
analysis and information available on either POD 2 or POD 
3, in an attempt to increase the predictive power by combin-
ing several parameters. The choice of POD 2 or POD 3 was 
made because it allows the washout effect of massive intra-
operative transfusions and fluid resuscitation to fade. while 
the differences in parameter values are still at a maximum. 
The models were then further evaluated, considering their 
overall accuracy. goodness of fit. and AUe. The best overall 
model. generated using information from POD 3. had a pre-
dictive accuracy of 92.7%. and is descnbed by the following 
expression: 
el - j 65 .. 0 15 • Blii ~ U Hi· PT ... l) 58· Crl 
p = 1 + e' ; 65 ." 15' B,l" II 10' t'1' ." 5S' Crt 
where P is the probability that a graft will fail. Bili is the 
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FIGURE 2. Serum transaminases. factor V. and prothrombin time for the first 5 postoperative days in patients with successful (nofail) and 
unsuccessful (fail) grafts. 
TABLE 2. AUC for individual parameters and the logistic 
regression (LRl model on PODs 2 and 3 
TABLE 3. ROC curve analysis showing the performance at 
LR model 
Bilirubin 
Creatinine 
Prothrombin time 
SOOT 
Lactate 
Factor V 
SGPT 
AKBR 
AUC day:.! 
MKU4~MKMR 
MKp4~MKM4 
0.76:.'.:0.05 
MKTO~MKMUT 
0.70:.'.:0.07 
MKSU~MKMT 
0.67:.'.:0.08 
0.66:.'.:0.08 
MKSM~MKMU 
AUC day 3 
MK9M~MKM4 
MKU9~MKMP 
0.79:.'.:0.05 
0.75:.'.:0.08 
MKT1~MKMT 
MKTR~MKMU 
MKT4~MKMU 
MKST~MKMU 
MKST~MKMU 
serum bilirubin, PT is prothrombin time. Cr is serum creati-
nine, and e is the base of the natural logarithms. The best 
model for POD 2 had an overall accuracy of 87 .8%. Their ROC 
curves. constructed using the individual probabilities esti-
mated by the models. had an AUC of 0.90:.'.:0.04 for POD 3 
and 0.84:.'.:0.05 for POD 2. These areas are no different from 
those of serum bilirubin for the same days (Table 2l. If we 
look at the individual performance of the 2 models. we can 
appreciate that if we set the cutoff value for the POD 3 model 
I Table 4) at a probability of failure of 0.73. we achieve perfect 
specificity, but the true-positive fraction is only 17tX. A cutoff 
value of 0.11 gives us a true-positive fraction of 751}. but the 
false-positive fraction increases to 13%. 
Analyses performed using log-transformed data. or the 
ratios of different parameters with respect to their initial 
values. did not improve their predictive ability. 
various critical result values for individual parameters 
and the logistic regression (LRl model on POD 2 
Cutoff value FPF" TPF" 
LR model 0.65 0.02 0.24 
0.41 0.06 0.38 
0.15 0.21 0.70 
0.02 0.85 0.99 
Bilirubin (mgldl l 21.2 0.03 0.16 
10.75 0.13 0.52 
6.35 0.32 0.86 
2.4 0.81 0.99 
Creatinine (mg/dll :.l,45 0.04 0.14 
1.85 0.26 0.62 
1.25 0.49 0.87 
0.75 0.S2 0.99 
Prothrombin time (sec' 26.35 0.01 O.lS 
16.55 0.19 0.55 
13.95 0.51 0.76 
12.35 0.86 0.92 
SGOT IIt.:IL) 4.391 0.01 rU3 
1.315 0.19 0.49 
472 0.53 0.76 
211 0.81 0.91 
" FPF. false-positive fraction: TPF. true-posItive fraction. 
DISCUSSION 
Given the lack of uniform definitions in this field. the first 
decision to make when studying outcome after liver trans-
plantation is how to define graft failure. In clinical practice. 
we would like to differentiate between ;3 broad categories: 
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TABLE 4. ROC curve analysis showing the performance at 
various critical result values for individual parameters 
and the logistic regression (LR) model on POD 3 
Cutoff value FPF' TPF" 
LR model 0.73 0.00 0.17 
0.47 0.02 0040 
0.11 0.13 0.75 
0.03 0043 0.96 
Bilirubin (mg/dJ) 23.5 0.02 0.16 
9.40 0.15 0.75 
6.70 0.26 0.90 
2.25 0.80 1.00 
Creatinine (mg/dl) 3.75 0.06 0.12 
1.85 0.29 0.73 
1.35 0.46 0.92 
0.75 0.80 0.99 
Prothrombin time (see) 23.00 0.01 0.15 
14.90 0.13 0.51 
13.00 0.42 0.75 
11.85 0.82 0.93 
Lactate (mmol/L) 5.50 0.01 0.16 
3.30 0.06 0040 
2.25 0.21 0.60 
1.00 0.81 0.93 
• FPF. false-positive fraction; TPF, true-positive fraction. 
those patients who will survive with a well-functioning graft, 
those who will survive but require retransplantation, and 
those who will die in the early posttransplant period (with or 
without retransplantation). Our definition was deliberately 
broad, and was that of either patient death or retransplan-
tation within 3 months of surgery. Patients who did not sur-
vive longer than 24 hr were excluded because there is not 
enough information available for analysis, and these cases 
seldom constitute a prognostic dilemma. We elected to use 3 
months as our final cutoff point because most of the deaths or 
graft losses that occur during the first year take place within 
90 days. For those patients transplanted at our institution in 
1991. patient survival was 81% at the end of 1 year, with a 
graft survival of 72%. Sixty-seven percent of the deaths and 
72% of the graft losses occurred within 90 days (unpublished 
datal. These figures include those losses that took place 
within 24 hr. 
We did not attempt to make a distinction between grafts 
that failed due to need for retransplantation and those due to 
patient death, since the small number of cases expected in 
the graft failure group would have precluded any meaningful 
statistical analysis. Another issue was whether to separate 
deaths that were seemingly unrelated to graft failure into a 
distinct category. Shaw et al. (15) have suggested a stratifi-
cation of posttransplantation deaths to study failures in a 
more systematic way. They divided patient deaths. 44 in their 
series of 180 liver transplants, into 4 categories, depending 
on whether they were directly related to pretransplantation 
morbidity, surgical complications, failures of immunosup-
pression, or unusual circumstances. Although this classifica-
tion provides a framework for further study, and is concep-
tually attractive in that it focuses our attention on different 
patient categories. we decided not to use it. It is often hard to 
determme why a graft failed or a patient died. Should a 
ruptured mycotic aneurysm be included among the technical 
failures or the unexpected deaths? If the rupture follows 
acute pancreatitis in a patient with hepatitis B, should that 
be grouped with pretransplant health conditions'? Is sepsis 
the prunary cause of death in a patient with marginal graft 
function, or just the terminal event, in the presence of liver 
failure? On the other hand, and especially if we are trying to 
study those factors that determine posttransplant morbidity 
and mortality, we need to exclude at least those unusual 
cases where we can be reasonably certain that the morbid 
event was unrelated to the procedure. At this point, we can 
give no strict rules. Each case should be considered on its own 
merits, and one should err on the side of over inclusion, 
rather than high selection. 
Seven patients died of documented bacterial sepsis. There 
were 3 instances of primary nonfunction, and an additional 4 
grafts were lost to severe ischemic injury. One patient died of 
pancreatitis, and another lost the liver to severe ongoing 
rejection. One patient died of cardiac arrhythmias 3 days 
after surgery, with no predisposing factors identified. In 
41.3%, graft failure was due to patient death from sepsis, 
another 41.3% were lost to either primary nonfunction or 
severe ischemic injury, which most of the time reflects the 
same pathologic process, and 17.4% were lost to miscella-
neous causes, such as pancreatitis, arrhythmias, and rejec-
tion. Sepsis continues to be the leading cause of death in liver 
transplant patients. In a study performed at our institution 
in 1986 (19), 52.5% of early deaths were due to infectious 
complications. and 71% ofICU deaths in the Cambridge pro-
gram had the same etiology (20). In contrast to an earlier 
series from our institution (19), no patients died of uncon-
trollable rejection. 
We did not specifically analyze the effect of Child-Pugh 
scores (21), a measure that, in the past. has not been useful 
in this setting (22). Our findings, when we consider indepen-
dently 4 of the 5 parameters used to calculate it (see Table 1), 
are in keeping with this. There were no differences in preop-
erative prothrombin time. serum albumin. or presence of as-
cites. The difference in preoperative serum bilirubin was only 
marginally significant (P=0.05), although this might have 
been a function of the large unequal variances and the rela-
tively small size of group II. rather than biological unimpor-
tance. There was also no difference in the fraction of patients 
whose bilirubin was greater than 3 mgldl (see Results). We 
find the Child-Pugh score less than useful for other reasons 
as well. Cirrhotic patients routinely receive infusions of al-
bumin solutions, either after large volume paracentesis or to 
correct some arbitrarily defined level of hypoalbuminemia. 
Although the latter practice is of dubious value, it seems to 
have become firmly entrenched. and it is now very difficult to 
determine what the baseline serum albumin was in a given 
patient. We also find encephalopathy to be difficult to assess 
in mechanically ventilated patients, who very often receive 
some form of sedation. 
Two preoperative factors that we found associated with 
outcome, namely serum creatinine and whether the patient 
was undergoing a retransplantation, are well-known risk fac-
tors. Serum creatinine has been Identified preVIOusly by our 
group as the best single preoperative indicator of short-term 
prognosis after liver transplantation (13), and retransplan-
tation continues to carry a significantly higher mortality 
1:23 ). 
The proportion of patients that were either ICU bound or 
on mechanical ventilation was higher in group II, although 
the difference was not significant. Thirty-two percent of 
group I patients were ICU bound. as opposed to 53% for 
group II (P=O.08). and 15.6% in group I were on mechanical 
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ventilation. compared with 23.5% in group II (P=O.4l. This is 
in contrast to a larger group of patients from our institution 
who were analyzed recently, in whom a higher urgency status 
and need for life support correlated with higher mortality 
124). The patients in our current study are different in at 
least 2 respects: we excluded those who did not survive longer 
than 24 hr or who were retransplanted after having been 
entered in the study. This probably included some of our 
sickest patients, and explains the different results. 
An interesting finding was the fact that a positive cytotoxic 
crossmatch had apparently no deleterious effects. All the 
positive cytotoxic crossmatches were found in group I 
(14.3%). Takaya et al. (25) have previously described the 
adverse effects of a positive cytotoxic cross match on patients 
treated with FK506 and low-dose steroids. Those with a posi-
tive crossmatch had I-year graft and patient survivals of 56% 
and 68%, respectively, as opposed to 82% and 86% for those 
with a negative crossmatch. In positive cross match patients, 
intraoperative blood usage was higher, similar to a previous 
observation made in high panel-reactive antibody patients by 
~larino et al. (26), and postoperative liver function took 
longer to normalize. In a small series reported later. the 
authors found that. in the case of a positive crossmatch. 
adding a higher steroid regimen and PGEI infusion allowed 
them to obtain results that were comparable to those seen 
with a negative crossmatch (27). This prompted a change in 
policy at our institution whereby, in the face of a positive 
crossmatch. patients receive a traditional methylpred-
nisolone burst and subsequent taper. All patients who can 
tolerate it are given a PGE 1 infusion during the first post-
transplant week. Although we were not specifically studying 
this point. our data are consistent with the notion that the 
use of high-dose steroids, and probably PGEI, ameliorates 
the untoward effects of a positive crossmatch (28). 
Several postoperative factors were associated with graft 
failure. Serum bilirubin was higher in group II throughout 
the early postoperative period (Fig. 1). This difference was 
due not only to higher preoperative levels, but also to the fact 
that bilirubin tended to rise even more in cases of graft fail-
ure. while It decreased slightly in patients WIth successtul 
;''Tafts. Renal function was also worse in group II patients, as 
retlected by a much higher serum creatinine throughout most 
of the early postoperative period (Fig. n ~lcCauley et al. 
have studied renal function after liver transplantation both 
III patients receiving CsA (29) and those receiving FK506 
1:30). They found a 39.4% incidence of posttransplant renal 
failure (serum creatinine greater than 3 mgldi), which corre-
lated strongly with mortality (29). Our initial experience 
showed that renal function also tends to deteriorate after 
liver transplantation under FK506 therapy (30), and the 
present data indicate that the association between renal dys-
function and liver allograft failure sull holds. The etiology of 
this renal dvsfunctlOn IS certainly multifactonal. with drug 
toxIcIty. extent of pre-existing liver disease. intraoperative 
hemodynamIC instability, and presence of sepsis playmg a 
role. 
AbnormalIties in blood coagulation are a hallmark of end-
stage liver disease. and have been used for many years to 
"auge allograft function (31). In this senes. prothrombin 
tImes on days :l through 4 were significantly higher. and 
factor V levels on days 2. 3, and 5 were sigmticantiy lower in 
patients who ultimately failed (Fig. 2). Factor V levels reach 
a nadir shortly after revascularization of the graft, and re-
turn to normal over the next several days (31). It has been 
suggested that a greatly depressed factor V level in the early 
postoperative period is a very good predictor of outcome, both 
in terms of the graft (1) and overall mortality (14)' Our 
results certainly support the idea that coagulation abnor-
malities parallel graft function and eventual outcome. How-
ever, the discriminating power of the tests, especially factor 
V, does not seem as good as initially thought. One problem 
with these 2 measurements (factor V and prothrombin time), 
and many others we rely upon, is that they can be affected 
significantly by replacement therapy that is far from stan-
dardized, even within the same institution. Different pa-
tients with the same degree of coagulopathy, as measured by 
standard testing, can receive significantly different amounts 
of replacement products depending on other factors, some of 
which can be largely subjective. Although we did not quantify 
the volume of replacement products that were administered, 
the number of patients who received one or more infusions of 
fresh-frozen plasma during a given 24-hr period was signifi-
cantly higher in group II on days 3 and 4, and of marginal 
significance on day 2 (data not shown, P<O.Ol for days 3 and 
4, and P=0.055 for day 2). It is unlikely, then, that the lesser 
derangements seen in group I were due to a better correction 
of their coagulopathy, if one was present. On the other hand. 
the differences between the groups would probably have been 
more pronounced if replacement therapy had been the same 
for both. 
The metabolic state of the patient. as reflected by the 
AKBR. oxygen consumption. and serum lactate are also con-
sidered important correlates of outcome. AKBR (Fig. 2) on 
POD 1 was significantly higher in group I, and after a log 
transformation of the data, the differences were also found to 
be significant on PODs 3 and 5. The discriminating power of 
AKBR in this series of patients was much lower than that 
quoted preVIOusly in the literature (3. 5), including reports 
from our institution (4 I. Factors that may explain this in-
clude the use of a different definitIon of graft failure. and the 
fact that we did not exclude from the analysis patients who 
were diabetic. had pancreatitis. or showed biochemical evi-
dence of starvation. Under these conditions. if we use the 
previously suggested AKBR value of less than 0.7 by POD 2 
as our cutoff point, ROC curve analysis shows the false-posi-
tive fraction would be 16%, while the true-positive fraction 
would be only 35%. 
Oxygen consumption Esl~F is decreased in cirrhotic pa-
tients (32 l. perhaps retlecting an abnormal supply depen-
dency in this population (33), As might be expected, this falls 
even further during the anhepatic phase (8,34). There have 
been attempts at correlating penoperative changes in oxygen 
consumption with graft outcome. but some series are limited 
by the small number of patients (8. 351. In a study of 125 liver 
recipients who had VD., measured at several points during 
transplantatIon. it was found that. except for 4 patients who 
had primary nontunctJon. there was a marked increase in 
VO.! after repertusion (36 I. In another report. based on 100 
consecutive patients. it was stated that failure of sl~ to 
increase above pre-an hepatic levels after reperfusion cor-
rectly identitied patients with subsequent graft failure iO.6% 
of the time. When used with postrepertusion serum glucose. 
to arrive at a -metabolic index." correct classification in-
creased to 92.4'70 of cases (9 I. The authors subdivided the 
r 
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patients into 2 groups: those who survived with normal liver 
function for more than 3 months (group 1. n=90) and those 
who had primary nonfunction requiring retransplantation 
within 24 hr (group 2. n=lO). It is unusual that a transplant 
program would encounter 100 consecutive patients who 
cleanly segregate into either one of these 2 categories. and it 
is not clear to us how applicable these findings are in more 
typical liver transplant populations. 
Information regarding oxygen consumption in the post-
transplant period is meager at best (37, 38). and there is only 
one report we are aware ofthat has looked at its relationship 
with early allograft failure (10). The authors reviewed retro-
spectively 86 patients who underwent primary liver trans-
plantation. and in whom complete hemodynamic profiles 
were obtained within 48 hr of admission to the leU. They 
found that V02 was significantly lower in the group of pa-
tients whose graft failed within the first month. while there 
were no differences in oxygen delivery (10). We found no 
difference in either D02 or V02 in this series. Our results may 
be due to a type II error. since the groups, especially the 
failure group, were relatively small. However. we believe that 
they are representative because these data were obtained 
prospectively, shortly after the patients had returned to the 
leu and had been allowed to rewarm to 36°C. This reduced 
the confounding effects of hypo- or hyperthermia. It also al-
lowed us to carry out the measurements while most patients 
were still recovering from the anesthetic. reducing the vari-
ability introduced by patient activity. 
Lactic acidosis is a common finding in fulminant liver fail-
ure. and has a negative correlation with survival (39). Dur-
ing liver transplantation. there is a progressive hyperlac-
tatemia. which usually peaks at the end of the anhepatic 
phase (J n It is likely due to diminished clearance by the 
liver. although tissue hypoxia may also playa role. We found 
that serum lactate was significantly higher in group II on 
both POD 2 and POD 5. In contrast to other reports (11 l. we 
did not lind any difference between groups in terms of the 
intraoperative peak serum lactate level. By itself. serum lac-
tate IS a poor discriminator. 
In fact. there is enough overlap between groups that no 
single parameter studied is very helpful when It comes to an 
individual patient. especially considering the decisions that 
might be contemplated. The same can be said for most of the 
trends we observe every day at the bedside. We all take 
comfort in the observation that "the patient's numbers are 
getting better." as if this were a reliable indicator of clinical 
improvement. when in reality this is not necessarily so. 
Clearly. if all liver function tests are unrelentingly deterio-
rating. the prognosis is poor. but these are not the problem-
atic cases we would like to sort out quickly. As we can see in 
Figures 1 and 2. liver function test results tend to move in the 
same directIOn whatever the outcome. However. there is one 
important exceptlon: serum bilirubin. which has been re-
garded as the most important indicator of clinical progress 
since the beginning of liver transplantation. However. al-
though we can say that a continued. rise In bilirubin portends 
a poor outcome. the individual variabilitv IS still such that it 
precludes us from formulating a consistent plan of action 
based solely on It. Serum creatinine stabilizes shortly after 
the transplant in the successful patients. while it continues 
to nse in the failure group. Renal dysfunction. however. can 
be caused by many factors. not the least Important being the 
very medications we use routinely in these patients. and this 
complicates its use as a clinical predictor. 
Even when we combine several parameters. we gain rela-
tively little in discriminating power. The best multivariate 
models we have generated. with information available on the 
second and third postoperative days. had an overall accuracy 
of 87.8% and 92.7%, respectively. As good as these numbers 
may sound, we must be very careful when we interpret them. 
especially since they are greatly affected by the prevalence of 
the condition we are trying to predict. ROC curve analysis 
provides us with a more realistic picture of the performance 
we can expect from a test, or multiple regression model, and 
it is independent of prevalence (18). Tables 3 and 4 show the 
individual performances as we vary the critical test result, 
that is, as we change what we consider to be the cutoff point 
that we will use to assign a patient to one group or another. 
Even with multivariate models, to detect most patients who 
are destined to fail we need to be willing to accept onerous 
false-positive fractions. It is instructive to see that even after 
extensive multivariate analyses, we can do no better than we 
would by just asking how jaundiced is the patient that day. 
We may be able to improve our models by gathering a 
larger sample. and then separating the presumably different 
categories that we elected to treat as one. It is also possible 
that we simply do not have enough information. because we 
are measuring the wrong things, or not measuring them of-
ten enough. It may be necessary to incorporate intraopera-
tive and donor variables. which we chose to leave out under 
the premise that their influence should translate into a rec-
ognizable postoperative state. Whatever we do. we should 
take a critical look at the results. and remember that a very 
small P-value cannot be equated to predictive ability. We can 
no longer accept misleading measurements. such as overall 
accuracy, that are greatly influenced by the prevalence of the 
condition we are trying to predict. It is especially important 
in the current fiscal climate. where we will be pressured into 
making allocation decisions based on a given predictive 
model. 
There is a growing feeling among us that the final answer 
is not going to be a simple matter of more data collection. so 
we can continue to take increasingly more elaborate snap-
shots. We are trying to describe complex. nonlinear systems 
that will very likely continue to resist our more traditional 
approaches. It may be time to borrow new tools. 
AcknowledRments. The authors thank Derek Angus. MD. for re-
VIewing the manUlicript and prOViding inSightful comments. 
REFERENCES 
1. Bilik R. Superina RA. Poon AO. Coagulation plasma factor levels 
are earlv indicators of gTaft nonfuncllon followmg liver trans-
plantation In children. J Pediatr Surl{ 1992: 27(3): 302. 
.) Moia M. ~1artlnelli l. Gridelli B. et al. mro~ostlc value of hemo-
static parameters after liver transplantation. J Hepatol 1992: 
15: 125. 
:3. Taki Y. Gubematls G. Yamaoka Y. et 81. pi~lficance of artenal 
ketone bodv ratio measurement In human liver transplanta-
tion. Transplantation 1990: 49(3): 535. 
I. Asonuma K Takava S. Selbv H. et al. The clinical significance of 
the artenal ketone body ratlo as an earlv Indicator of gTaft 
viability In human liver transplantation. Transplantation 
1991: 51( 1l: 164. 
'S. Takada Y. OzaJu N. Rinl{e B. et al. ReceIver operating charac-
· ' 
1036 TRANSPLANTATION VoL 57, No.7 
teristics (ROC) analysis of the ability of arterial ketone body 
ratio to predict graft; outcome after liver transplantation-its 
sensitivity and specificity. Transplant Int 1992; 5: 23. 
6. Egawa H. Shaked A. Konishi Y. et a1. Arterial ketone body ratio 
in pediatric liver transplantation. Transplantation 1993; 55(3): 
522. 
7. Oellerich M. Burdelski M. Ringe B. et a1. Lignocaine metabolite 
formation as a measure of pre-transplant liver function. Lan-
cet 1989; 1: 640. 
8. Svensson KL. Persson H. Henriksson A. et al. Whole body gas 
exchange: amino acid and lactate clearance as indicators of 
initial and early allograft viability in liver transplantation. 
Surgery 1989; 105: 472. 
9. Steltzer H. Tuchy G, Hiesmayr M, et al. Peri-operative liver 
graft function: monitoring using the relationship between 
blood glucose and oxygen consumption during anesthesia. An-
aesthesia 1992; 47: 955. 
10. Takaya S. Nonami T. Selby R, et al. The relationship of systemic 
hemodynamics and oxygen consumption to early allograft; fail-
ure after liver transplantation. Transplant Int 1992; 6: 73. 
11. Steltzer H. Tuchy G, Hiesmayr M, Zimpfer M. Oxygen kinetics 
during liver transplantation: the relationship between delivery 
and consumption. J Crit Care 1993; 8(1): 12. 
12. Shaw BW. Wood RP, Gordon RD, et al. Influence of selected 
patient variables and operative blood loss on six-month sur-
vival following liver transplantation. Semin Liver Dis 1985; 
5(4): 385. 
13. Cuervas-Mons V. Millan 1. Gavaler JS, et al. Prognostic value of 
preoperatively obtained clinical and laboratory data in predict-
ing survival following orthotopic liver transplantation. Hepa-
tology 1986; 6(5): 922. 
14. Stock PG. Estrin JA, Fryd DS. et al. Factors influencing early 
survival after liver transplantation. Am J Surg 1989; 157: 215. 
15. Shaw BW. Wood RP. Stratta RJ. et a1. Stratlfying the causes of 
death in liver transplant recipients. Arch Surg 1989; 124: 895. 
16. Baliga p. Merion RM. Turcotte JG. et al. Preoperative risk factor 
assessment in liver transplantation. Surgery 1992; 112: 704. 
17. Members of the American College of Chest Physicians/Society of 
Critical Care Medicine Consensus Conference Committee. 
Amencan College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference: Definitions for sepsis and or-
gan failure and guidelines for the use of innovative therapIes in 
sepsIs. Crit Care Med 1992: 20: 864. 
18. Metz CEo Basic pnnclples of ROC analysis. Semin Nucl Med 
1978: 8: 283. 
19. Cuervas-Mons V. Martinez AJ. Dekker A. et a1. Adult liver 
transplantation: an analysis of the early causes of death in 40 
consecutive cases. Hepatology 1986; 6(3): 495. 
20. Park GR. Gomez Arnau M. Lindop JR. et at. Mortality during 
intensive care after orthotopIC liver transplantation. Anaesthe-
sia 1989; 44: 959. 
21. Pugh RNH. Murray Lyon 1M. Dawson JL. et al. Transection of 
the oesophagus for bleeding oesophageal varices. Br J Surg 
1973: 60: 646. 
22. Shaw BW. Exclusion criteria for liver transplantation. Trans-
plant Proc 1989: 21(3): 3484. 
23. Starzl TE. Demetris AJ. Liver transplantation: a 31-year per-
spective. Part III. Curr Probl Surg 1990; 27: 181. 
24. Bronsther 0, Fung JJ, Tzakis A. Starzl TE. Prioritization and 
organ distribution for liver transplantation. JAMA 1994; 
271(2): 140. 
25. Takaya S, Bronsther 0, Iwaki Y. et a1. The adverse impact on 
liver transplantation of using positive cytotoxic crossmatch 
donors. Transplantation 1992: 53: 400. 
26. Marino IR. Weber T. Kang YG. et a1. HLA alloimmunization and 
blood requirements in orthotopic liver transplantation. Trans-
plant Proc 1989; 21(1): 789. 
27. Takaya S, Iwaki Y, Starzl TE. Liver transplantation in positive 
cytotoxic crossm.atch cases using FK506. high-dose steroids, 
and prostaglandin E1. Transplantation 1992; 54: 927. 
28. Marino IR. Doyle HR, Starzl TE. Conventional immunosuppres-
sive drugs. In: Thomson AW, Starzl TE, eds. Immunosuppres-
sive drugs: advances in anti-rejection therapy. London: 
Edward Arnold. 1994. 
29. McCauley J, Van Thiel DH, Stanl TE, Puschett JB. Acute and 
chronic renal failure in liver transplantation. Nephron 1990; 
55: 121. 
30. McCauley J, Fung JJ, Todo S. et al. Changes in renal function 
after liver transplantation under FK506. Transplant Proc 
1991; 23(6): 3143. 
31. Groth CG. Changes in coagulation. In: Stan I TE. ed. Experience 
in hepatic transplantation. Philadelphia: W.B. Saunders. 
1969: 159. 
32. Moreau R. Lee SS. Soupison T. et al. Abnormal tissue oxygen-
ation in patients with cirrhosis and liver failure. J Hepatol 
1988; 7: 98. 
33. Moreau R. Lee SS. Hadengue A, et a1. Relationship between 
oxygen transport and oxygen uptake in patients with cirrhosis: 
effects of vasoactive drugs. Hepatology 1989; 9(3): 427. 
34. Steib A. Freys G, Gohard R, et a1. Tissue oxygenation during 
liver transplantation. Crit Care Med 1992; 20(7): 977. 
35. Groh J. Welte B, Gerhard M, et a1. Value of total body oxygen 
consumption as a parameter of graft function after liver trans-
plantation. Transplant Proc 1992; 24(6): 2696. 
:36. Gubematis G. Bomscheuer A. Taki Y. et al. Total oxygen con-
sumption. ketone body ratio and a speCIal score as early indi-
cators of irreversible liver allograft dysfunction. Transplant 
Proc 1989: 21(1): 2279. 
37. Shanbhogue RL. Bistrian BR. Jenkins RL. et a1. Increased pro-
tein catabolism without hypermetabolism after human ortho-
topic liver transplantation. Surgery 1987; 101(2): 146. 
38. Delafosse B, Faure JL. Bouffard Y. et a1. Liver transplantation-
energy expenditure. nitrogen loss. and substrate oxidation rate 
in the first two postoperative days. Transplant Proc 1989; 
21(1): 2453. 
39. Bihsri D. Gimson AE. Waterson M. Williams R. Tissue hypoxia 
during fulminant hepatic failure. Crit Care Med 1985: 13: 
1034. 
Received 1 July 1993. 
Accepted 14 September 1993. 
T 
I 
